Details of the Drug

General Information of Drug (ID: DMRJ3ND)

Drug Name
CD19 and CD20 CAR-T Cells
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1/2 [1]
leukaemia 2A60-2B33 Phase 1/2 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0QB1O
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma